BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:America/Phoenix X-WR-TIMEZONE:America/Phoenix BEGIN:VEVENT UID:1461@azbio.org DTSTART;TZID=America/Phoenix:20200429T090000 DTEND;TZID=America/Phoenix:20200429T094500 DTSTAMP:20200429T034317Z URL:https://www.azbio.org/events/vaccines-our-best-long-term-defense SUMMARY:Vaccines—our best long-term defense - Webinar - 29 Apr 20 09:00 DESCRIPTION:\nVaccines—our best long-term \;defense\nWednesday\, Apri l 29th at 12 pm EST (9 AM AZ)\nRob Boulanger and \;Marc \;Pelletie r\n\nNot a treatment but a cure. \;The 1918 influenza (Spanish Flu) pa ndemic was the most severe pandemic in recent history\, where 1/3 of the h uman race was affected by this avian H1N1 flu virus and roughly 15-20% of those infected died. If not for improvements in health and science\, the S ARS-CoV-2 pandemic would likely have affected far more individuals and the lethality rate would certainly have been much higher. Influenza viruses s till claim the lives of over 50\,000 Americans every year. This number cou ld be reduced dramatically if everyone received their influenza vaccines e very year. Vaccination\, when possible\, provides the best long-term defen se against viral and bacterial infections and subsequently a pandemic\, by preparing our body’s own infection defense \;system.\n\nThe types o f vaccines\, the methods of manufacture and the safety profiles have impro ved dramatically since Edward Jenner first injected 8 year old James Phill ips in 1796. The time between the identification of the pathogen and the m anufacture of potential vaccine candidate has been reduced from years to w eeks. \;Multiple platforms exist \;within our biopharmaceutical co mpanies providing several potential candidates for a commercial product. M any of the cell culture based biopharmaceutical manufacturing facilities i n existence today lend themselves well to vaccine manufacturing\, providin g a huge potential for large scale manufacturing in response to a pandemic . Rob Boulanger will provide a case study example of how equipment used in a typical mAb facility could be used for large scale manufacturing of a S ARS-CoV-2 \;Vaccine.\n\nJoin us to learn how to reconfigure what is av ailable in your production arsenal and scale it safely while rapidly deplo ying it in a GMP compliant way takes a nimble and responsive team of \ ;experts.\n\nRegister here! CATEGORIES:webinars LOCATION:Webinar\, Anywhere\, USA\, United States X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Anywhere\, USA\, United Sta tes;X-APPLE-RADIUS=100;X-TITLE=Webinar:geo:0,0 END:VEVENT BEGIN:VTIMEZONE TZID:America/Phoenix X-LIC-LOCATION:America/Phoenix BEGIN:STANDARD DTSTART:20190430T090000 TZOFFSETFROM:-0700 TZOFFSETTO:-0700 TZNAME:MST END:STANDARD END:VTIMEZONE END:VCALENDAR